Receipt of a decision from the National Centre for Research and Development regarding the partial reimbursement of funds from the CT-02 project grant

Current report no. 21/2025

Drafting date: 16 May 2025

Subject: Receipt of a decision from the National Centre for Research and Development regarding the partial reimbursement of funds from the CT-02 project grant.

Legal basis: Art. 17(1) MAR – confidential information.

With reference to current report No. 21/2023 of June 6, 2023, current report No. 24/2023 of June 20, 2023, and current report No. 27/2023 of July 7, 2023 (“Current Reports”), the Management Board of Captor Therapeutics S.A. with its registered office in Wrocław (“the Company”) announces that today the Company received decision No. 9/2025 issued by the National Centre for Research and Development (“NCBR”) regarding the implementation of project CT-02 (POIR.01.01.01-00-0741/19: “Development and advancement of non-toxic ligase ligands and their application in the treatment of autoimmune diseases and blood system cancers”) (hereinafter referred to as the “Decision” and the “Project,” respectively).

Pursuant to the Decision, the NCBR obliged the Company to return part of the funds received as co-financing for the Project, i.e. the amount of PLN 4,093,244.48 (in words: four million ninety-three thousand two hundred forty-four zlotys and forty-eight groszy), which represents approximately 64% of the amount originally requested by the NCBR, together with accrued interest.

In the original demand, about which the Company informed in its current report 21/2023 of June 6, 2023, the NCBR called on the Company to return the entire amount of Project funding received in the amount of PLN 6,388,361.19 (in words: six million three hundred eighty-eight thousand three hundred sixty-one zlotys nineteen groszy) together with interest. The Company contested this position, providing detailed explanations and documentation concerning the course of the project implementation, as reported in Current Reports.

In the Decision, the NCBR also stated that the amount of PLN 2,245,116.71 (in words: two million two hundred forty-five thousand one hundred sixteen zlotys and seventy-one groszy) is not subject to repayment, and therefore the administrative proceedings in this respect have been discontinued.

The Company also informs that in 2023, it established a provision for the liability to the NCBR for the settlement of the Project in the amount of PLN 7.4 million. As at December 31, 2024, the amount of the above provision is PLN 7.9 million.

The Company is currently analysing the content of the Decision in terms of form and substance, in particular in the context of the decision to appeal against such a ruling. The Company maintains its position that the Project was implemented in accordance with the current state of scientific knowledge and that the changes in its course served to maintain its innovative character and effectiveness.

The Company will provide further information on the progress of the case in accordance with applicable law.